Related Experiment Video
Updated: Aug 6, 2026
08:05
Electrophysiological Methods to Assess Peripheral Pain Block in an Anesthetized Rat
Published on: November 21, 2025
Impact of Stark II Rules on interventional pain practices
1Health Law Group of Arent Fox Klinter Plotkin and Kahn, PLLC, Washington, D.C. 20036, USA. sarrailw@arentfox.com
Pain Physician
|August 12, 2006
Summary
The Stark Law, enacted in 1989 and amended in 1993 (Stark II), regulates physician financial relationships for Medicare and Medicaid services. Phase I of the Stark II Final Rules impacts interventional pain medicine practices.
Area of Science:
- Healthcare Law
- Medical Practice Regulation
- Physician Financial Relationships
Background:
- The original Stark Law (Stark I) was enacted in 1989 to prevent physician self-referrals for Medicare-reimbursed clinical laboratory services.
- Stark II amendments in 1993 expanded prohibitions to Medicaid and included "designated health services."
Purpose of the Study:
- To describe Phase I of the Stark II Final Rules.
- To analyze the impact of these rules on interventional pain medicine practices.
Main Methods:
- Review of Stark I and Stark II legislation.
- Analysis of HCFA's Phase I Final Stark Rules published January 4, 2001.
- Examination of implications for interventional pain medicine.
Main Results:
- Phase I of the Stark II Final Rules addressed key areas including referral definitions, volume/value of referrals, in-office ancillary services exceptions, group practice definitions, and designated health services.
- These rules introduced significant compliance considerations for physicians in interventional pain medicine.
Conclusions:
- Understanding the nuances of Stark II Phase I is crucial for interventional pain medicine practices to ensure compliance.
- The regulations aim to curb conflicts of interest in physician self-referrals for designated health services.
Related Concept Videos
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...